现有病毒疫苗用于防治新冠肺炎的可行性分析

新冠肺炎的爆发严重危害人类健康和公共卫生安全，已引起全球范围内的高度关注。预防病毒性疾病最有效的措施是接种疫苗，但是目前还没有专门针对新型冠状病毒的疫苗。考虑到疫情的严重性，对同为RNA病毒的流感病毒、其他冠状病毒相关疫苗的研究进行了综述，并通过对这些病毒氨基酸水平的序列比对发现，新冠病毒的棘突糖蛋白与H1N1、H3N2、B型Victoria系和B型Yamagata系流感病毒的血凝素糖蛋白之间具有一定的相似性。由于血凝素糖蛋白是目前商用流感疫苗的主要作用靶点，因此推测，现有季节性商用流感疫苗在新冠肺炎的防控方面可能也具有一定的应用潜能。除此之外，由于新冠病毒与SARS冠状病毒的棘突糖蛋白和核蛋白之间均具有高度的相似性，而SARS冠状病毒疫苗又主要从上述两种蛋白研制而来，因此建议在短期内，可以将目前正在研制的SARS冠状病毒疫苗作为新冠病毒特效疫苗的替代物来使用。

Exploring preventive measures for COVID-19 based on the existing virus vaccines

The outbreak of COVID-19 is seriously endangering human and public health. It has caused great concern all around the world. The most effective measure to prevent viral diseases is vaccination. But there has no specific vaccine been approved for this disease yet. Considering the serious effect of the epidemic,this article reviewed the related vaccines research on influenza viruses and coronaviruses, and their amino acid sequences were compared. The results show that there are some similarity between the spike of 2019-nCoV and hemagglutinin from influenza A virus and influenza B virus. The hemagglutinin of influenza is the major targets of current commercial sensonal influenza vaccines which imply that vaccines might be beneficial for prevention of COVID-19. Besides that, because of the high similarity between spike and nucleocapsid of SARS-CoV and 2019-nCoV, we believe that the SARS-CoV vaccine may be an alternative that can be used for the control of COVID-19 in the short term.